177 related articles for article (PubMed ID: 8261867)
1. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Liu X
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
[TBL] [Abstract][Full Text] [Related]
2. A new approach to the treatment of malignant effusion.
Li DJ; Wang YR; Tan XY; Wang HZ; Yao XD; Ba DN
Chin Med J (Engl); 1990 Dec; 103(12):998-1002. PubMed ID: 2127253
[TBL] [Abstract][Full Text] [Related]
3. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
4. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2.
Liu X; Li D; Zhang C; Ba D; Liu J; Wan T; Li Z; Jin Y; He Y
Chin Med Sci J; 1993 Sep; 8(3):186-9. PubMed ID: 8142637
[TBL] [Abstract][Full Text] [Related]
5. [Intrapleural administration of LAK cells combined with rIL2 in the treatment of advanced lung cancer with malignant pleural effusion].
Mao G; Gao Z; Wang Q
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):83-4, 127. PubMed ID: 7553956
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with malignant pleural effusions due to advanced lung cancer by transfer of autologous LAK cells combined with rIL-2 or rIL-2 alone.
Li D; Wang Y; Yao X; Shao J; Chen Y; Ba D
Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):51-5. PubMed ID: 2371266
[No Abstract] [Full Text] [Related]
7. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells.
Guo YS; Xing ZL
Chin Med J (Engl); 1994 Dec; 107(12):903-5. PubMed ID: 7882727
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.
Yasumoto K; Mivazaki K; Nagashima A; Ishida T; Kuda T; Yano T; Sugimachi K; Nomoto K
Cancer Res; 1987 Apr; 47(8):2184-7. PubMed ID: 3493843
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive immunotherapy of cancer patients with lymphokine-activated killer cells].
Taguchi T; Domoto K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):914-21. PubMed ID: 3494428
[TBL] [Abstract][Full Text] [Related]
10. [Adoptive immunotherapy of malignant pleural effusion with TIL/rIL2 (tumor-infiltrating lymphocytes/recombinant interleukin 2)].
Han B; Jia Y; Zhou M
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):91-3, 128. PubMed ID: 7553959
[TBL] [Abstract][Full Text] [Related]
11. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
Li D; Zhang X; Song Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
[TBL] [Abstract][Full Text] [Related]
12. [Experimental and clinical studies on intrapleural instillations of interleukin-2 (IL-2) in patients with malignant pleural effusion].
Suzuki H
Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1922-31. PubMed ID: 2608022
[TBL] [Abstract][Full Text] [Related]
13. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
[TBL] [Abstract][Full Text] [Related]
14. [Clinical application of adoptive immunotherapy in patients with progressive lung cancer].
Cho T; Yoshizawa H
Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1543-8. PubMed ID: 7798747
[No Abstract] [Full Text] [Related]
15. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
16. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
17. [The cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells].
Guo Y; Xing Z
Zhonghua Jie He He Hu Xi Za Zhi; 1995 Apr; 18(2):80-2, 127. PubMed ID: 7553955
[TBL] [Abstract][Full Text] [Related]
18. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
19. [Induction by local injections of IL-2 of antitumor effector cells and secondary production of cytokines in malignant pleural effusion].
Sone S; Yanagawa H; Nii A; Ozaki T; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Aug; 30(8):1434-40. PubMed ID: 1434216
[TBL] [Abstract][Full Text] [Related]
20. The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.
Suzuki H; Abo S; Kitamura M; Hashimoto M; Izumi K
Surg Today; 1993; 23(12):1053-9. PubMed ID: 8118118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
